Please login to the form below

Not currently logged in
Email:
Password:

Genzyme wins Scottish approval for Renvela

Genzyme UK can supply Renvela within NHS Scotland after securing Scottish Medicine Consortium approval

Genzyme UK, a subsidiary of sanofi-aventis group, has received approval from the Scottish Medicine Consortium (SMC) to use Renvela within NHS Scotland as a treatment for hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Renvela is a medication for the control of serum phosphorous in patients with CKD. Kidney failure causes levels of phosphate to rise in the blood, as the patient's kidneys are not able to excrete excess phosphate into the urine. Phosphorous build up is also associated with calcification of certain vessels.

Dr Alan Jardine, professor of renal medicine and head of the undergraduate medical school at University of Glasgow, said: "The availability of Renvela offers an efficacious addition to this class of agent, where existing therapies may have limited efficacy and poor patient compliance."

13th April 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics